San Francisco, 22 October 2018:
According
to a report published by Grand View Research, Inc.; the In-Situ
Hybridization (ISH) market is expected to reach a valuation of
around USD 1.84 billion by 2025.
Increasing prevalence of
chronic diseases such as cancer along with demand for rapid diagnostic
techniques can propel the market during the forecast period (2014 to 2025). In
addition, increasing occurrence of genetic disorders, leukemia, solid tumors, autism,
and other conditions can support the market growth.
Growing demand for molecular
diagnostic tools in clinical research and diagnosis is likely to increase
demand for ISH in the years to come. Introduction of real-time and automated
diagnostic kits for accurate and rapid diagnosis of cytogenetic modifications
is also expected to create positive outlook for the market. Development of
advanced probe-based technologies are also supporting the market growth. For
instance, Silver ISH (SISH) assay technology, a type of Chromogenic ISH (CISH),
is one of the emerging technologies in the market. In addition, growing R&D
related to application of ISH in genetic diseases and testing of infectious
diseases is anticipated to fuel the market growth in the coming years.
Worldwide In-Situ
Hybridization (ISH) market can be segmented on the basis of type, technology,
product, application, end-use, and region. Based on type, the market can be
categorized into DNA and RNA. The DNA segment held for the major share due to
its high adoption in clinical research and diagnosis of diseases caused due to
bacteria. The RNA probes segment is likely to exhibit lucrative CAGR in the
coming years owing to its low cost and high stability. As per, technology, the
market can be characterized into fluorescent In-Situ Hybridization (FISH) and
chromogenic In-Situ Hybridization (CISH).
In 2016, the FISH estimated for the largest market share in terms of
revenue due to its increasing use in molecular diagnostics.
Access
Research Report of In Situ
Hybridization Market@ www.grandviewresearch.com/industry-analysis/in-situ-hybridization-ish-market
On the basis of product, the
market split into instruments, kits and probes, software, and services. As per
application, the market can be fragmented into cancer, developmental biology,
cytogenetics, infectious diseases, and others.
In 2016, instruments accounted
for the largest share due to increasing demand from diagnostic and research
laboratories as it provides several advantages including portability, easy to
use, and cost-efficiency. The kits and probes segment is likely to display a
lucrative CAGR during the forecast period. Growing cases of target diseases
like cancer is likely to increase demand for these products. The service
segment is anticipated to exhibit high growth during the forecast period due to
rise in outsourcing of molecular biology services among the researchers and
pathologists.
Based on end-use, the market
classified into research and diagnostic laboratories, contract research
organizations (CROs), academic institutes, and others. In 2016, the research
and diagnostic laboratories segment estimated for the major share due to rise
in applications of molecular cytogenetics in diagnostics. The Contract Research
Organizations (CROs) segment is likely to show lucrative gains in the years to
come due to growing trend of outsourcing molecular biology services.
Browse more reports of this category by
Grand View Research at: www.grandviewresearch.com/industry/biotechnology
Geographically, the market can
be divided into North America, Europe, Asia Pacific, Latin America, and Middle
East & Africa. IN 2016, North America estimated for the largest market
share due to high expenditure for research and government effort for
development of novel diagnostic tools.
Europe represents the
second-largest market. Growth in this region can be attributed to existence of
government organizations like European Diagnostic Manufacturers Association
(EDMA), which emphasizes on development of IVD industry in the region.
Asia Pacific is projected to
display lucrative CAGR in the years to come. This growth can be associated with
growing government investment to support research in molecular biology and
increasing awareness among the researchers regarding benefits of ISH technology
in diagnostics.
Prominent companies operating
in the market include Bio-Rad Laboratories, Inc.; PerkinElmer, Inc.;
NeoGenomics Laboratories, Inc.; Oxford Gene Technology.; and Thermo Fisher
Scientific.
The market is extremely
competitive, and some companies are dominating the due to their extensive
product range and geographic reach across the world. Participants are
concentrating more on enhancement of distribution channel and operational
reformation.
Access
Press Release of In Situ Hybridization Market@ www.grandviewresearch.com/press-release/global-in-situ-hybridization-ish-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business decisions,
we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and
healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment